Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:26:03 EDT Thu 12 Jun 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ATAI - ATAI LIFE SCIENCES NV - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATAI - Q0.12.04·2.470.12.232.451    2.64  1.0308:04:19Jun 0215 min RT 2¢

Recent Trades - All 1 today
Time ETExPriceChangeVolume
08:04:19Q2.280.05500
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-02 06:00U:ATAINews Releaseatai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
2025-05-29 08:30U:ATAINews Releaseatai Life Sciences to Participate in Upcoming Investor Conferences
2025-05-20 07:00U:ATAINews Releaseatai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
2025-05-14 07:00U:ATAINews Releaseatai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
2025-05-13 07:01U:ATAINews Releaseatai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
2025-03-17 08:00U:ATAINews Releaseatai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
2025-03-11 07:00U:ATAINews Releaseatai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
2025-03-05 07:00U:ATAINews Releaseatai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
2025-02-24 16:10U:ATAINews Releaseatai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
2025-02-20 07:00U:ATAINews Releaseatai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
2025-02-12 22:47U:ATAINews Releaseatai Life Sciences Announces Pricing of Public Offering of Common Shares
2025-02-12 16:01U:ATAINews Releaseatai Life Sciences Announces Proposed Public Offering of Common Shares
2025-01-28 07:00U:ATAINews Releaseatai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
2025-01-10 07:00U:ATAINews Releaseatai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
2024-11-13 08:00U:ATAINews Releaseatai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
2024-11-11 07:30U:ATAINews ReleaseAltimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
2024-10-15 08:00U:ATAINews Releaseatai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
2024-09-04 07:00U:ATAINews Releaseatai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-13 07:10U:ATAINews Releaseatai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-13 07:00U:ATAINews Releaseatai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)